#VisualAbstract: Early discontinuation of endocrine therapy may increase risk of breast cancer recurrence in premenopausal women
Click to read the study in Clinical Cancer Research.
Tag: breast cancer survival
#VisualAbstract: Pyrotinib plus capecitabine improves progression-free survival in HER2⁺ metastatic breast cancer
Click to read the study in The Lancet Oncology.
#VisualAbstract: Endocrine therapy plus oral S-1 improves invasive disease-free survival in patients with ER⁺ breast cancer
Click to read the study in The Lancet Oncology.
First-degree family history of breast cancer associated with increased risk of breast cancer in older women
1. In this prospective cohort study, first-degree family history of breast cancer was associated with increased risk of breast cancer ...
Palbociclib taken with letrozole increases progression-free survival in breast cancer patients
1. Patients with previously untreated estrogen receptor ER positive (ER+), human epidermal growth factor receptor 2 (HER2) negative breast cancer ...
Dose-dense adjuvant chemotherapy not better than standard therapy for high-risk early breast cancer
1. This randomized, open label, phase 3 trial found that dose-dense adjuvant chemotherapy did not significantly improve breast cancer recurrence-free ...
70-gene signature test may accurately determine prognosis in early stage breast cancer
1. In women with early stage breast cancer and discordant genomic and clinical risk, the 5-year survival rate without distant ...
Extending adjuvant letrozole treatment may reduce breast cancer recurrence: The MA.17R trial
1. Extended-use adjuvant letrozole therapy was associated with significant reduction in breast cancer-free survival but not overall survival, compared to ...
Adaptive treatment using veliparib-carboplatin shows benefit in breast cancer
1. The addition of veliparib-carboplatin to standard therapy in treating triple-negative breast cancer patients showed higher rates of pathological complete ...